176 assets in HER2 Positive Breast Carcinoma

Therapeutic assets addressing HER2 Positive Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Gsk 5733584 HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Her-2 Pulsed Dc1 HER2 Positive Breast Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
Hrs-4508 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Hrs-6209 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Inavolisib HER2 Positive Breast Carcinoma	GBG Forschungs GmbH	P2	CCC (48)
Ivonescimab HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
js207 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Lasofoxifene HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Leuporelin HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Margetuximab HER2 Positive Breast Carcinoma	MedSIR	P2	CCC (48)
Metformin HER2 Positive Breast Carcinoma	Qamar Khan	P2	CCC (48)
Mitoxantrone HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
N-Desmethyl-4-Hydroxytamoxifen HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Nebivolol HER2 Positive Breast Carcinoma	Ain Shams University	P2	CCC (48)
Parstuzumab HER2 Positive Breast Carcinoma	Henan Cancer Hospital	P2	CCC (48)
Patritumab Deruxtecan HER2 Positive Breast Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P1/2	CCC (48)
Pexidartinib HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Rezatapopt HER2 Positive Breast Carcinoma	PMV Pharmaceuticals, Inc	P1/2	CCC (48)
Rilvegostomig HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Rivoceranib HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Sarilumab HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Shr-4602 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Shr-A1921 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Tislelizumab HER2 Positive Breast Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (48)
tqb2868 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Transcon Il-2 Β/Γ HER2 Positive Breast Carcinoma	Ascendis Pharma Oncology Division A/S	P1/2	CCC (48)
Transcon Tlr7/8 Agonist HER2 Positive Breast Carcinoma	Ascendis Pharma Oncology Division A/S	P1/2	CCC (48)
Trebananib HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Trilaciclib HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Veliparib HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Vepdegestrant HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
vv1 HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Wokvac Vaccine HER2 Positive Breast Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
Montmorillonite ((Al1.33-1.67Mg0.33-0.67)(Ca0-1Na0-1)0.33Si4(Oh)2O10.Xh2O) HER2 Positive Breast Carcinoma	Jiangsu HengRui Medicine Co., Ltd.	P1	CC (47)
Nelitolimod HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CC (46)
Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CC (45)
Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CC (44)
Spartalizumab HER2 Positive Breast Carcinoma	SOLTI Breast Cancer Research Group	P2	CC (44)
[177lu]lu-aby-271 HER2 Positive Breast Carcinoma	Affibody	P1	CC (43)
Abbv-461 HER2 Positive Breast Carcinoma	Calibr, a division of Scripps Research	P1	CC (43)
Bbo-10203 HER2 Positive Breast Carcinoma	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P1	CC (43)
Bl-M17D1 HER2 Positive Breast Carcinoma	SystImmune Inc.	P1	CC (43)
Ceralasertib HER2 Positive Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
cgt4255 HER2 Positive Breast Carcinoma	Cogent Biosciences, Inc.	P1	CC (43)
Clbr001 HER2 Positive Breast Carcinoma	Calibr, a division of Scripps Research	P1	CC (43)
ct-0525 HER2 Positive Breast Carcinoma	Carisma Therapeutics Inc	P1	CC (43)
h3b-6545 HER2 Positive Breast Carcinoma	Eisai Inc.	P1	CC (43)
iam1363 HER2 Positive Breast Carcinoma	Iambic Therapeutics, Inc	P1	CC (43)
Pidnarulex HER2 Positive Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)

Showing 101 to 150 of 176 assets

PreviousPage 3 of 4Next